Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25806402 | 1.00 | PIK3CD (0.33) | PIK3CDJAK1TYRO3IRAK4 | |
| SCHEMBL21286839 | 1.00 | PIK3CD (0.33) | PIK3CDJAK1TYRO3IRAK4 | |
| SCHEMBL25806613 | 1.00 | PIK3CD (0.33) | PIK3CDJAK1TYRO3IRAK4 | |
| SCHEMBL20051455 | 1.00 | PIK3CD (0.33) | PIK3CDJAK1TYRO3IRAK4 | |
| Hydrochloric Acid SCHEMBL25301238 | 0.99 | PIK3CD (0.33) | PIK3CDJAK1TYRO3IRAK4 | |
| Hydrochloric Acid SCHEMBL31382910 | 0.99 | PIK3CD (0.33) | PIK3CDJAK1TYRO3IRAK4 | |
| SCHEMBL22764179 | 0.86 | IRAK4 (0.36) | IRAK4 | |
| SCHEMBL21286732 | 0.85 | IRAK4 (0.37) | JAK1IRAK4 | |
| SCHEMBL27153783 | 0.85 | IRAK4 (0.37) | JAK1IRAK4 | |
| SCHEMBL30822849 | 0.85 | IRAK4 (0.37) | JAK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393492-A2 | METHOD FOR SYNTHESIZING FUROIMIDAZOPYRIDINE COMPOUND, POLYMORPHIC SUBSTANCE AND POLYMORPHIC SUBSTANCE OF SALT | Hangzhou Highlightll Pharmaceutical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4248967-A2 | SYNTHESIS METHOD OF FUROIMIDAZOPYRIDINE COMPOUND, CRYSTAL FORM OF FUROIMIDAZOPYRIDINE COMPOUND, AND CRYSTAL FORM OF SALT THEREOF | Hangzhou Highlightll Pharmaceutical Co., Ltd. (CN) | 2023-09-27 | — | — | EP | disclosed |
| EP-4248966-A2 | SYNTHESIS METHOD OF FUROIMIDAZOPYRIDINE COMPOUND, CRYSTAL FORM OF FUROIMIDAZOPYRIDINE COMPOUND, AND CRYSTAL FORM OF SALT THEREOF | Hangzhou Highlightll Pharmaceutical Co., Ltd. (CN) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023125102-A1 | METHOD FOR SYNTHESIZING 1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDINE COMPOUND | 杭州高光制药有限公司 | 2023-07-06 | — | — | WO | disclosed |
| EP-3509591-B1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | HIGHLIGHTLL PHARMACEUTICAL HAINAN CO LTD (CN) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020244348-A1 | SYNTHESIS METHOD OF FUROIMIDAZOPYRIDINE COMPOUND, CRYSTAL FORM OF FUROIMIDAZOPYRIDINE COMPOUND, AND CRYSTAL FORM OF SALT THEREOF | 广州高瓴制药有限公司 | 2020-12-10 | — | — | WO | disclosed |
| WO-2020244349-A1 | METHOD FOR SYNTHESIZING FUROIMIDAZOPYRIDINE COMPOUND, POLYMORPHIC SUBSTANCE AND POLYMORPHIC SUBSTANCE OF SALT | 广州高瓴制药有限公司 | 2020-12-10 | — | — | WO | disclosed |
| US-10738060-B2 | JAK1 selective inhibitors and uses thereof | TLL Pharmaceutical, LLC (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190256523-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | HANGZHOU HIGHLIGHTII PHARMACEUTICAL CO., LTD (CN) | 2019-08-22 | — | — | US | disclosed |
| WO-2018067422-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | LIANG CONGXIN (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738060-B2 | JAK1 selective inhibitors and uses thereof | JAK1, JAK3, JAK2 | PIK3CD 371/4885JAK1 1/4885TYRO3 59/4885 |
| US-20190256523-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | JAK1, JAK3, JAK2 | PIK3CD 378/4885JAK1 1/4885TYRO3 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.